1. ¹Institut Paoli-Calmettes, Marseille, France
2. ²Hopital Salvator, Marseille, France
3. ³University of York, York, UK
4. ⁴Etablissement Français du Sang Alpes-Méditerranée, Marseille, France

Correspondence: C Bagnis, EFS Alpes Méditerranée, Département de thérapie cellulaire et génique, 149 Boulevard Baille, 13005, Marseille, France. E-mail: claude.bagnis@efs.sante.fr

Received 7 March 2003; Revised 1 May 2003; Accepted 8 May 2003.

Abstract

In a preclinical model for prostate cancer gene therapy, we have tested lentiviral vectors as a practical possibility for the transfer and long-term expression of the EGFP gene both in vitro and in vivo. The human prostate cancer cell lines DU145 and PC3 were transduced using experimental conditions which permitted analysis of the expression from a single proviral vector per cell. The transduced cells stably expressed the EGFP transgene for 4 months. After injection of the transduced cell populations into Nod-SCID mice a decrease in EGFP was only observed in a minority of cases, while the majority of tumors maintained transgene expression at in vitro levels. In vivo injection of viral vector preparations directly into pre-established subcutaneous or orthotopic tumor masses, obtained by implantation of untransduced PC3 and DU145 cells led to a high transduction efficiency. While the efficiency of direct intratumoral transduction was proportional to the dose of virus injected, the results indicated some technical limitations inherent in these approaches to prostate cancer gene therapy.